论文部分内容阅读
目的:观察老年2型糖尿病(T2DM)患者口服降糖药血糖控制不佳时,分别采用诺和锐30与诺和灵30联合治疗的临床疗效。方法:选择61例口服降糖药物控制不佳(糖化血红蛋白>7%)的老年糖尿病患者,将其随机分成2组,分别采用诺和锐30或诺和灵30治疗,疗程为12周,观察患者用药后空腹血糖(FBG)、餐后2小时血糖(2hPBG)和糖化血红蛋白(HbAlc)的变化及安全性。结果:经治疗,两组老年T2DM患者的血糖控制均有显著改善,诺和锐30组较诺和灵30组血糖控制更好、胰岛素用量更少、低血糖发生率更低。结论:对于口服降糖药控制不佳的老年T2DM患者,加用诺和锐30较诺和灵30效果更显著,且安全性更高。
OBJECTIVE: To observe the clinical efficacy of combination therapy of Novo-Rui-30 with Novolin in elderly patients with type 2 diabetes mellitus (T2DM) undergoing poor blood sugar control. Methods: A total of 61 elderly diabetics with poor glycemic control (HbA1c> 7%) were enrolled in this study. They were randomly divided into two groups. The patients were treated with Novartis 30 or Novolin 30 for 12 weeks. Changes of fasting blood glucose (FBG), 2h postprandial blood glucose (2hPBG) and HbAlc in patients after medication and safety. Results: After treatment, glycemic control was significantly improved in both elderly T2DM patients. Novo-Thru 30 group had better glycemic control, less insulin dosage, and lower incidence of hypoglycemia. CONCLUSIONS: For older T2DM patients with poorly controlled oral hypoglycemic agents, the combination of Novo-Rui 30 and Neo-Ling 30 is more effective and safer.